ADAMTS13 is a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13.
It is also known as von Willebrand factor-cleaving protease (VWFCP).
ADAMTS (short for a disintegrin and metalloproteinase with thrombospondin motifs)
ADAMST is a family of multidomain extracellular protease enzymes.
19 members of this family have been identified.
ADAMTS proteases functions include processing of procollagens and von Willebrand factor.
ADAMST13 is the plasma metalloproteinases that cleaves ultra large von Willebrand factor multimers down to physiologic size.
vWF Multimers of physiologic size mediate thrombosis by binding platelets to the sub endothelium where needed.
Ultra large VWF multipliers in contrast cause excessive binding of platelets throughout the body.
In most cases the deficiency is acquires when antibodies form that either destroy or block the function of ADAMSTS 13.
In rare cases people are born without the ADAMTS 13 protease.
ADAMTS proteases cleave aggrecan, versican, brevican and neurocan, and are key in remodeling enzymes of the extracellular matrix.
ADAMTS proteases have roles in connective tissue organization, coagulation, inflammation, arthritis, angiogenesis and cell migration.
Most cases of ((thrombotic thrombocytopenic purpura))arise from autoantibody-mediated inhibition of ADAMTS13.
It is a zinc-containing metalloprotease enzyme that cleaves von Willebrand factor (vWf), a large protein involved in blood clotting.
ADAMTS13 is secreted into the blood and degrades large vWf multimers, decreasing their activity.
ADAMTS 13 activity levels are usually above 50% and if the activity below falls below 10% the diagnostis is likely TTP, whereas levels exceeding 20% indicate the diagnosis is unlikely.
ADAMTS13 Gene location is Chromosome 9
Thrombotic thrombocytopenic purpura (TTP), one of the microangiopathic hemolytic anemias is characterized in its familial form by the presence in plasma of unusually large von Willebrand factor multimers (ULVWF).
ADAMTS13 has specific epitopes on its surface have been shown to be the target of inhibitory antibodies.
Low levels of ADAMTS13 are also associated with an increased risk of arterial thrombosis, including myocardial infarction and cerebrovascular disease.